Trial Profile

A First-in-Human, Open-Label, Dose Escalation and Expansion Trial of BTX-9341 in Participants With Advanced and/or Metastatic Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BTX 9341 (Primary) ; Fulvestrant (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors BioTheryX

Most Recent Events

17 Nov 2025 According to a BioTheryX media release, topline data readout from Phase 1a clinical trial expected in Q1 2026.
17 Nov 2025 Status changed from recruiting to active, no longer recruiting, according to a BioTheryX media release.
29 Jul 2024 Planned number of patients changed to 82.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com